MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03188172 |
Recruitment Status :
Active, not recruiting
First Posted : June 15, 2017
Last Update Posted : May 14, 2024
|
Sponsor:
University of Leeds
Collaborators:
Myeloma UK
Celgene
Janssen, LP
Information provided by (Responsible Party):
University of Leeds
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | October 1, 2025 |
Estimated Study Completion Date : | May 31, 2026 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):